Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome

European Journal of Haematology

Volumn 88, Issue 1, 2012, Pages 52-60

  Buchholz, Stefanie ^a   Dammann, Elke ^a   Stadler, Michael ^a   Krauter, Juergen ^a   Beutel, Gernot ^a   Trummer, Arne ^a   Eder, Matthias ^a   Ganser, Arnold ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Clofarabine; Leukemia; Myelodysplastic syndrome; Stem cell transplantation

Indexed keywords

ACICLOVIR; AZACITIDINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUCONAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; REDUCED INTENSITY CONDITIONING; RELAPSE FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; WHOLE BODY RADIATION;

ADENINE NUCLEOTIDES; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; CYCLOSPORINE; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELODYSPLASTIC SYNDROMES; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 83655184694     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01703.x     Document Type: Article

References (32)

1. Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001;112:118-26.
2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-83.
3. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-74.
4. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70years or older) with acute myeloid leukemia. Blood 2010;116:4422-9.
5. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003;101:64-70.
6. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-5.
7. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:212-23.
8. Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003;21:1480-4.
9. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55years. Blood 2003;102:3052-9.
10. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-24.
11. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003;102:2021-30.
12. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83.
13. Sayer HG, Kröger M, Beyer J, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003;31:1089-95.
14. Stelljes M, Bornhauser M, Kroger M, et al. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood 2005;106:3314-21.
15. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5675-87.
16. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005;105:940-7.
17. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50years of age or older. Blood 2006;108:45-51.
18. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638-45.
19. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010;28:2389-95.
20. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010;28:549-55.
21. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-9.
22. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295-304.
23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204-17.
24. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15:825-8.
25. Kühnau W, Böhm I, Krawczak M, Schmidtke J. A paternity case with apparently conflicting multilocus and single-locus DNA typing results. Electrophoresis 1997;18:1598-601.
26. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
27. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-56.
28. Marks R, Potthoff K, Hahn J, et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008;112:415-25.
29. Farag S, Wood LL, Schwartz LE, et al. Phase I trial of high-dose clofarabine and busulfan as a myeloablative regimen prior to allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute leukemia. Blood 2008;112:415-25.
30. Mineishi S, Magenau J, Pawarode A, et al. Myeloablative conditioning with clofarabine and busulfan X 4 (CloBu4) is well tolerated, facilitates secure engraftment, and exhibits significant anti-tumor activity against non-remission hematologic malignancies including AML. Blood 2008;114:198 ASH Annual Meeting Abstract 2150.
31. Mineishi S, Magenau J, Tobai H, et al. Allogeneic hematopoietic stem cell transplantation with Clofarabine/ Busulfan x 4 (CloBu4) conditioning exhibits significant anti-tumor activity in non-remission hematologic malignancies, especially in AML. Blood 2009;116:35 ASH Annual Meeting Abstract 35.
32. Casper J, Wolff D, Knauf W, et al. Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. J Clin Oncol 2010;28:3344-51.